会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 53. 发明申请
    • 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
    • 6-芳基-7-卤代 - 咪唑并[1,2-a]嘧啶作为抗癌剂
    • US20080255157A1
    • 2008-10-16
    • US11903100
    • 2007-09-19
    • Nan ZhangSemiramis Ayral-Kaloustian
    • Nan ZhangSemiramis Ayral-Kaloustian
    • A61K31/519A61P35/04
    • C07D487/04
    • This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.
    • 本发明涉及某些6-芳基-7-卤代咪唑并[1,2-a]嘧啶或其药学上可接受的盐,以及含有所述化合物或其药学上可接受的盐的组合物,其中所述化合物是可用于 通过促进微管聚合治疗哺乳动物的癌症。 本发明还涉及治疗或抑制哺乳动物中癌性肿瘤细胞和相关疾病的生长的方法,并进一步提供了治疗或预防表达多重耐药性(MDR)或耐多药耐药性的癌性肿瘤的方法 在有需要的哺乳动物中,所述方法包括向所述哺乳动物施用有效量的所述化合物或其药学上可接受的盐。
    • 57. 发明申请
    • 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
    • 6-芳基-7-卤代 - 咪唑并[1,2-a]嘧啶作为抗癌剂
    • US20050065167A1
    • 2005-03-24
    • US10950542
    • 2004-09-24
    • Nan ZhangSemiramis Ayral-Kaloustian
    • Nan ZhangSemiramis Ayral-Kaloustian
    • A61K31/519A61P35/00C07D487/02C07D487/04
    • C07D487/04
    • This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.
    • 本发明涉及某些6-芳基-7-卤代咪唑并[1,2-a]嘧啶或其药学上可接受的盐,以及含有所述化合物或其药学上可接受的盐的组合物,其中所述化合物是可用于 通过促进微管聚合治疗哺乳动物的癌症。 本发明还涉及治疗或抑制哺乳动物中癌性肿瘤细胞和相关疾病的生长的方法,并进一步提供了治疗或预防表达多重耐药性(MDR)或耐多药耐药性的癌性肿瘤的方法 在有需要的哺乳动物中,所述方法包括向所述哺乳动物施用有效量的所述化合物或其药学上可接受的盐。
    • 60. 发明授权
    • Semiconductor wafer
    • 半导体晶圆
    • US06469361B2
    • 2002-10-22
    • US09946390
    • 2001-09-04
    • Nan Zhang
    • Nan Zhang
    • H01L2900
    • H01L21/32139G03F7/095G03F7/16H01L21/0274H01L21/31144
    • Techniques for etching a wafer layer using multiple layers of the same photoresistant material and structures formed using such techniques are provided. In a method, first, multiple layers of the same photoresist material are formed over the wafer layer to form a composite photoresist layer. The composite photoresist layer is patterned and developed to form a patterned photoresist layer. Exposed portions of the wafer layer are then removed using the pattern photoresist layer. Each of the multiple layers of photoresist may, for example, be formed to a maximum rated thickness for the photoresist material. Structures formed using this process may have relatively small dimensions (e.g., widths of 5 microns or less or a spacing or pitch of 5 microns or less). In addition, structures may also have sidewalls which are relatively long, smooth, and/or vertical.
    • 提供了使用相同光致抗蚀剂材料的多层蚀刻晶片层的技术和使用这些技术形成的结构。 在一种方法中,首先在晶片层上形成多层相同的光致抗蚀剂材料以形成复合光致抗蚀剂层。 将复合光致抗蚀剂层图案化并显影以形成图案化的光致抗蚀剂层。 然后使用图案光致抗蚀剂层去除晶片层的暴露部分。 例如,可以将多层光致抗蚀剂中的每一层形成为光致抗蚀剂材料的最大额定厚度。 使用该方法形成的结构可以具有相对小的尺寸(例如,5微米或更小的宽度或5微米或更小的间距或间距)。 此外,结构还可以具有相对长,平滑和/或垂直的侧壁。